An essential step in the diagnosis of Alzheimer’s disease involves clearly articulating your symptoms. It can be beneficial to seek input from a close family member or friend to provide insights into your symptoms and their impact on your everyday life. Evaluations of memory and cognitive abilities are also crucial in diagnosing Alzheimer’s disease.
To exclude other potential causes for your symptoms, blood tests and brain imaging are employed. These tests can also identify specific proteins in the brain that are associated with Alzheimer’s disease. Ultimately, these diagnostic tools assist healthcare professionals in accurately identifying the underlying cause of dementia symptoms.
Historically, a definitive diagnosis of Alzheimer’s disease was only possible post-mortem, through microscopic examination of brain tissue to identify plaques and tangles. However, advancements in medical science now allow healthcare professionals and researchers to diagnose Alzheimer’s disease with greater certainty during a person’s lifetime.
This improved diagnostic accuracy is achieved through a combination of tests, frequently incorporating biomarker assessments. Biomarkers are indicators that can reveal the presence of plaques and tangles in the brain. Biomarker testing includes specialized positron emission tomography (PET) scans of the brain. Furthermore, amyloid and tau proteins, key markers of Alzheimer’s, can be measured in blood plasma or cerebrospinal fluid (CSF), the fluid surrounding the brain and spinal cord. Recent progress has led to blood biomarker tests with enhanced accuracy in predicting the likelihood of amyloid presence in the brain.
Initially primarily used in clinical research settings, biomarker tests are increasingly being integrated into routine clinical practice. Healthcare professionals now utilize them alongside other diagnostic tests to enhance the accuracy of Alzheimer’s disease diagnosis. Biomarker tests also offer valuable information about the stage of the disease, whether it is in its early or later phases.
Diagnostic Tests for Alzheimer’s Disease
The diagnostic process for Alzheimer’s disease typically encompasses several key evaluations:
Physical and Neurological Examination
A fundamental component of the diagnosis of Alzheimer’s disease is a thorough physical and neurological exam conducted by a healthcare professional. This examination may involve assessing:
- Reflexes
- Muscle tone and strength
- Gait and balance, including the ability to rise from a chair and walk
- Sensory functions, specifically sight and hearing
- Coordination
Laboratory Blood Tests
Blood tests play a crucial role in ruling out other medical conditions that can manifest with symptoms similar to Alzheimer’s, such as memory loss and confusion. These conditions may include thyroid disorders or deficiencies in vitamin levels.
Emerging blood tests are capable of measuring levels of beta-amyloid protein and tau protein, which are directly related to Alzheimer’s pathology. However, it’s important to note that the availability of these advanced blood tests is not yet widespread, and insurance coverage may vary.
Mental Status and Neuropsychological Assessments
Healthcare professionals often employ brief mental status tests to initially evaluate a patient’s memory and cognitive skills. More comprehensive neuropsychological testing provides a more detailed analysis of cognitive function, allowing for comparisons against individuals of similar age and educational backgrounds. These detailed assessments are invaluable for establishing a baseline diagnosis and for monitoring symptom progression over time.
Brain Imaging Techniques
Brain scan images for diagnosis of Alzheimer’s disease
Brain imaging plays a vital role in the diagnosis of Alzheimer’s disease. Fluorodeoxyglucose PET (FDG PET) scans are a valuable tool in visualizing brain activity and identifying patterns indicative of Alzheimer’s. FDG PET scans reveal areas in the brain where glucose metabolism, essential for energy, is impaired. In the image provided, you can see comparative scans: a healthy brain exhibiting robust metabolism (black and blue areas), a brain with mild cognitive impairment showing reduced metabolism, and a brain affected by Alzheimer’s disease with significantly compromised metabolism (green, yellow, and red areas indicating worsening metabolism as the disease progresses).
Beyond FDG PET, other brain imaging techniques are employed to identify structural changes and rule out conditions other than Alzheimer’s that might cause similar symptoms, such as strokes, traumatic brain injury, or brain tumors. Furthermore, cutting-edge imaging tests are increasingly available in specialized medical centers and research settings. These advanced techniques can pinpoint specific brain changes characteristic of Alzheimer’s disease, such as the presence of amyloid plaques and neurofibrillary tangles.
Imaging techniques for assessing brain structure include:
- Magnetic Resonance Imaging (MRI): MRI utilizes radio waves and a powerful magnetic field to generate detailed images of the brain. MRIs are sensitive enough to detect shrinkage in specific brain regions associated with Alzheimer’s disease. Moreover, MRI scans are crucial for excluding other conditions that could be responsible for the observed symptoms. MRI is generally favored over CT scans for dementia evaluation. MRIs are also routinely performed before initiating certain Alzheimer’s medications and during treatment to monitor for any potential side effects.
- Computerized Tomography (CT) Scan: CT scans, employing specialized X-ray technology, produce cross-sectional images of the brain. CT scans are primarily used to rule out conditions like brain tumors, strokes, and head injuries.
PET scan technology extends beyond metabolic imaging and can capture images of the disease process itself. During a PET scan, a minute amount of radioactive tracer is introduced into the bloodstream to highlight specific features within the brain. PET imaging modalities relevant to Alzheimer’s disease diagnosis include:
- Fluorodeoxyglucose (FDG) PET Imaging: As previously discussed, FDG PET scans visualize glucose metabolism in the brain. Characteristic patterns of reduced metabolism in specific brain regions can aid in differentiating Alzheimer’s disease from other forms of dementia.
- Amyloid PET Imaging: This specialized PET technique directly measures the presence and density of amyloid plaques in the brain. While primarily used in research settings, amyloid PET imaging may be utilized clinically in cases with atypical presentations or very early-onset dementia symptoms.
- Tau PET Imaging: Tau PET imaging quantifies neurofibrillary tangles, another hallmark lesion of Alzheimer’s disease, within the brain.
In certain clinical scenarios, particularly when symptoms progress rapidly or dementia develops at a younger age, analysis of cerebrospinal fluid (CSF) may be performed to measure amyloid and tau levels directly.
The Future of Alzheimer’s Diagnostic Tests
Extensive research has validated the utility of biomarker tests in detecting biological indicators of Alzheimer’s disease in the brain. These tests, used in conjunction with other diagnostic tools, significantly enhance the accuracy of Alzheimer’s disease diagnosis after symptoms have emerged. While biomarker tests hold promise for preclinical detection of Alzheimer’s, their current application is primarily in individuals already exhibiting symptoms. The availability of advanced biomarker tests can vary depending on location and healthcare settings.
Genetic testing is generally not recommended for the majority of individuals undergoing diagnosis of Alzheimer’s disease. However, genetic testing may be considered for individuals with a strong family history of early-onset Alzheimer’s disease. It is crucial for anyone considering genetic testing to consult with a genetic counselor to thoroughly discuss the potential risks and benefits before proceeding.
Care at Mayo Clinic
More Information
Treatment of Alzheimer’s Disease
Alzheimer’s disease treatment strategies encompass medications to manage symptoms and, more recently, newer therapies aimed at slowing the progression of cognitive and functional decline. These newer disease-modifying treatments are specifically approved for individuals in the early stages of Alzheimer’s disease.
Medications for Alzheimer’s Symptoms and Disease Modification
Medications for Alzheimer’s disease can be categorized into those that address symptomatic relief and those designed to modify the underlying disease course.
Two main classes of medications are used to manage symptoms:
- Cholinesterase Inhibitors: These medications work by enhancing communication between nerve cells in the brain. They achieve this by preserving acetylcholine, a chemical messenger that is depleted in the brains of individuals with Alzheimer’s disease. Cholinesterase inhibitors are often the first-line medications prescribed, and many patients experience modest improvements in cognitive symptoms. Furthermore, they may also alleviate behavioral symptoms such as agitation and depression. These medications are available in oral forms and as skin patches. Commonly prescribed cholinesterase inhibitors include donepezil (Aricept, Adlarity), galantamine, and rivastigmine transdermal patch (Exelon). Common side effects can include gastrointestinal issues (diarrhea, nausea, loss of appetite) and sleep disturbances. In individuals with pre-existing heart conditions, serious side effects like irregular heartbeat are possible.
- Memantine (Namenda): Memantine operates through a different brain cell communication pathway and is indicated for slowing symptom progression in moderate to severe Alzheimer’s disease. It is sometimes used in combination with cholinesterase inhibitors for enhanced effect. Side effects are relatively infrequent but may include dizziness and confusion.
Recently, the Food and Drug Administration (FDA) has approved newer medications specifically designed to slow the decline in thinking and function caused by Alzheimer’s disease. These disease-modifying agents work by preventing the clumping of amyloid plaques in the brain. They are prescribed for individuals with mild Alzheimer’s disease and mild cognitive impairment due to Alzheimer’s disease.
These newer medications include:
- Lecanemab-irmb (Leqembi): Lecanemab is administered as an intravenous (IV) infusion every two weeks. Potential side effects include infusion-related reactions such as fever, flu-like symptoms, nausea, vomiting, dizziness, changes in heart rate, and breathing difficulties.
- Donanemab-azbt (Kisunla): Donanemab is given as an IV infusion every four weeks. Side effects may include flu-like symptoms, nausea, vomiting, headache, breathing problems, and blood pressure fluctuations.
A significant concern with lecanemab and donanemab is the potential for brain swelling (ARIA-E) or small brain bleeds (ARIA-H). In rare cases, brain swelling can be severe, leading to seizures and other serious neurological symptoms. Extremely rarely, brain bleeds can be fatal. The FDA recommends baseline brain MRI scans before initiating treatment and regular MRIs during treatment to monitor for ARIA.
Individuals carrying a specific genetic variant, APOE ε4, appear to have a higher risk of these serious side effects. Genetic testing for APOE ε4 is recommended by the FDA before starting treatment with these medications.
Caution is advised for individuals taking blood thinners or with other risk factors for brain bleeding, as these factors may increase the risk of ARIA with lecanemab or donanemab.
Ongoing research is further investigating the potential risks and long-term efficacy of lecanemab and donanemab. Research is also exploring their effectiveness in individuals at risk of Alzheimer’s disease, including those with a family history of the disease.
In addition to these Alzheimer’s-specific medications, other medications, such as antidepressants, may be prescribed to manage behavioral symptoms associated with Alzheimer’s disease.
Creating a Safe and Supportive Environment for Alzheimer’s Patients
Adapting the living environment to the needs of a person with Alzheimer’s disease is a critical component of care. Establishing consistent daily routines and simplifying tasks that rely heavily on memory can significantly improve quality of life.
Strategies to support a person’s well-being and functional abilities include:
- Designating specific, consistent locations for essential items like keys, wallets, and mobile phones to prevent loss.
- Securely storing medications and using daily checklists to ensure proper dosage.
- Setting up automatic bill payments and direct deposit for finances.
- Ensuring the person with Alzheimer’s carries a mobile phone with location tracking and programmed important phone numbers.
- Installing alarm sensors on doors and windows for safety.
- Maintaining a predictable schedule for appointments, ideally on the same day and time.
- Using calendars or whiteboards to track daily schedules and encouraging the habit of checking off completed tasks.
- Removing unnecessary furniture, clutter, and throw rugs to minimize fall risks.
- Installing sturdy handrails on stairs and in bathrooms for support.
- Ensuring comfortable, well-tractioned footwear.
- Reducing the number of mirrors, as reflections can be confusing or frightening for some individuals with Alzheimer’s.
- Ensuring the person with Alzheimer’s carries identification or wears a medical alert bracelet.
- Surrounding the home with meaningful photos and familiar objects to promote comfort and recognition.
More Information
Clinical Trials for Alzheimer’s Disease
Explore Mayo Clinic studies actively recruiting participants for new treatments, interventions, and diagnostic tests aimed at preventing, detecting, treating, or managing Alzheimer’s disease.
Alternative Medicine Approaches for Alzheimer’s Disease
A wide array of herbal remedies, vitamins, and supplements are promoted for cognitive health and for preventing or delaying Alzheimer’s disease. However, clinical trials evaluating these alternative therapies have yielded mixed and largely inconclusive results. Currently, there is limited scientific evidence to support their effectiveness as treatments for Alzheimer’s disease.
Some alternative treatments that have been investigated include:
- Vitamin E: While vitamin E has not been shown to prevent Alzheimer’s, high daily doses (2,000 international units) may modestly delay symptom worsening in individuals with mild to moderate Alzheimer’s. However, study findings have been inconsistent, and further research is needed to confirm safety and efficacy before routine recommendation. It’s crucial to be aware that supplements, including vitamin E, can interact with prescription medications.
- Omega-3 Fatty Acids: Omega-3 fatty acids, derived from fish or supplements, have been suggested to potentially lower dementia risk. Nevertheless, clinical trials have not demonstrated a benefit for treating existing Alzheimer’s disease symptoms.
- Curcumin: Curcumin, derived from turmeric, possesses anti-inflammatory and antioxidant properties that have been hypothesized to influence brain processes. To date, clinical trials have not found curcumin to be beneficial in treating Alzheimer’s disease.
- Ginkgo: Ginkgo biloba extract has been studied for its potential cognitive benefits. A large-scale study funded by the National Institutes of Health found no evidence that ginkgo prevents or delays Alzheimer’s disease.
- Melatonin: Melatonin, a supplement often used for sleep regulation, is under investigation for its potential to manage sleep disturbances in individuals with dementia. Some research suggests that melatonin may worsen mood in certain individuals with dementia, and more research is needed.
It is essential to consult with your healthcare team before using any herbal remedies, vitamins, or supplements, especially if you are taking medications for Alzheimer’s disease or other health conditions, to ensure a safe and coordinated treatment plan.
Lifestyle Modifications and Home Remedies for Alzheimer’s Disease
Adopting healthy lifestyle habits is beneficial for overall well-being and may also play a role in maintaining brain health in the context of Alzheimer’s disease.
Exercise
Regular physical activity is an integral part of a comprehensive Alzheimer’s treatment plan. Activities such as daily walking can improve mood, maintain joint and muscle health, and support cardiovascular function. Exercise also promotes restful sleep and can alleviate constipation. The benefits of exercise extend to caregivers as well.
Individuals with Alzheimer’s who have mobility challenges can still engage in physical activity through stationary cycling, stretching with resistance bands, or chair exercises. Community centers and online resources often offer exercise programs specifically designed for older adults.
Nutrition
Individuals with Alzheimer’s disease may experience changes in eating habits, such as forgetting to eat, losing interest in meals, or making less healthy food choices. Dehydration and constipation can also become issues due to reduced fluid intake.
Nutritional strategies to consider:
- Offer Healthy and Appealing Options: Provide favorite healthy foods that are easy to eat and require minimal preparation.
- Encourage Hydration: Ensure adequate fluid intake by offering water and other healthy beverages throughout the day. Limit caffeine intake, as it can exacerbate restlessness, disrupt sleep, and increase urinary frequency.
- Nutritious Shakes and Smoothies: When eating becomes challenging, high-calorie, healthy shakes and smoothies, supplemented with protein powders, can provide essential nutrients.
Social Engagement and Activities
Maintaining social connections and engaging in meaningful activities can help preserve cognitive skills and enhance overall well-being for individuals with Alzheimer’s disease. Focus on activities that are enjoyable and personally meaningful. Examples include:
- Listening to and enjoying music or dancing
- Reading or listening to audiobooks
- Gardening or engaging in crafts
- Participating in social events at senior centers or memory care facilities
- Interacting with children
Coping and Support for Alzheimer’s Disease
Individuals living with Alzheimer’s disease experience a wide spectrum of emotions, including confusion, frustration, anger, uncertainty, grief, and depression.
Caregivers can provide crucial emotional support by actively listening, offering reassurance that life can still be fulfilling, providing practical assistance, and striving to maintain the person’s dignity and self-respect.
Creating a calm and predictable home environment can minimize behavioral issues. Unfamiliar situations, excessive noise, and large gatherings can trigger anxiety. Pressuring someone with Alzheimer’s to remember information or perform complex tasks can also induce anxiety. When someone with Alzheimer’s becomes agitated, clear thinking becomes even more challenging.
Caring for the Alzheimer’s Caregiver
Providing care for a person with Alzheimer’s disease is both physically and emotionally demanding. Caregivers commonly experience feelings of anger, guilt, stress, worry, grief, and social isolation. Caregiving stress can also negatively impact the caregiver’s own physical health.
Prioritizing self-care is essential for caregivers. Strategies for caregiver well-being include:
- Educating yourself about Alzheimer’s disease to better understand the condition and its progression.
- Seeking information and guidance from healthcare professionals, social workers, and other professionals involved in care.
- Enlisting support from friends and family members when needed.
- Scheduling daily breaks for respite.
- Maintaining social connections and spending time with friends.
- Attending to your own health needs, including regular medical check-ups, healthy eating, and exercise.
- Joining a caregiver support group for emotional support and shared experiences.
- Utilizing local adult day care centers or respite care services when feasible.
Counseling and local support services can be invaluable resources for both individuals with Alzheimer’s and their families. Contact your local Alzheimer’s Association affiliate to connect with support groups, healthcare professionals, occupational therapists, and access resources and referrals, including information on home care agencies, residential care facilities, telephone helplines, and educational seminars.
Preparing for Your Medical Appointment for Suspected Alzheimer’s Disease
Medical evaluation for memory loss or cognitive decline typically involves a collaborative approach. If you are concerned about memory problems or related symptoms, it is highly recommended to bring a close relative or friend to your healthcare appointment. A companion can provide support and assist in answering questions during the consultation.
If you are accompanying someone with memory issues to a medical appointment, your role may include providing historical information and your observations about changes you have noticed. This teamwork approach is a vital aspect of effective medical care.
Your healthcare professional may refer you to specialists such as a neurologist, psychiatrist, neuropsychologist, or other specialists for more in-depth evaluation.
What You Can Do to Prepare for Your Appointment
To maximize the effectiveness of your appointment, prepare by writing down comprehensive information to share with your healthcare provider. This information may include:
- Medical History: Detailed past and current diagnoses and relevant family medical history.
- Medical Team Information: Names and contact information for current physicians, mental health professionals, or therapists.
- Medications: A complete list of prescription medications, over-the-counter drugs, vitamins, herbal supplements, and other supplements.
- Symptoms: Specific examples of memory changes or cognitive difficulties you have experienced.
What to Expect From Your Doctor During the Appointment
Your healthcare professional will ask detailed questions to understand the nature of your memory changes or other cognitive symptoms. Questions may include:
- What specific memory symptoms are you experiencing? When did you first notice them?
- Are your symptoms progressively worsening, or do they fluctuate?
- Have you stopped engaging in certain activities, such as managing finances or shopping, due to cognitive challenges?
- How would you describe your current mood? Do you feel depressed, sadder, or more anxious than usual?
- Have you experienced instances of getting lost while driving or in familiar environments?
- Has anyone expressed concern about your driving abilities?
- Have you noticed any alterations in your usual reactions to people or events?
- Do you experience changes in your energy levels (more, less, or the same as usual)?
- What medications are you currently taking, including vitamins and supplements?
- Do you consume alcohol? If so, how much?
- Have you noticed any tremors or difficulties with walking?
- Are you experiencing challenges remembering appointments or medication schedules?
- Have you had your hearing and vision recently tested?
- Is there a family history of memory problems, Alzheimer’s disease, or dementia?
- Do you act out your dreams during sleep (e.g., punching, flailing, shouting, or screaming)? Do you snore?
Alzheimer’s disease care at Mayo Clinic
Symptoms & causes
Doctors & departments
Nov. 08, 2024
- Jankovic J, et al., eds. Alzheimer disease and other dementias. In: Bradley and Daroff’s Neurology in Clinical Practice. 8th ed. Elsevier; 2022. https://www.clinicalkey.com. Accessed Aug. 23, 2024.
- Alzheimer’s disease fact sheet. National Institute on Aging. https://www.nia.nih.gov/health/alzheimers-disease-fact-sheet. Accessed Aug. 23, 2024.
- Livingston G, et al. Dementia prevention, intervention and care: 2024 report of the Lancet standing Commission. Lancet. 2024; doi:10.1016/S0140-6736(24)01296-0.
- Chen L, et al. Plasma tau proteins for the diagnosis of mild cognitive impairment and Alzheimer’s disease: A systematic review and meta-analysis. Frontiers in Aging Neuroscience. 2022; doi:10.3389/fnagi.2022.942629.
- Dementia. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/dementia. Accessed Aug. 23, 2024.
- Alzheimer’s disease and related dementias. Centers for Disease Control and Prevention. https://www.cdc.gov/aging/aginginfo/alzheimers.htm. Accessed Aug. 23, 2024.
- What is dementia? Symptoms, types, and diagnosis. National Institute on Aging. https://www.nia.nih.gov/health/diagnosing-dementia. Accessed Aug. 23, 2024.
- How biomarkers help diagnose dementia. National Institute on Aging. https://www.nia.nih.gov/health/biomarkers-dementia-detection-and-research. Accessed Aug. 23, 2024.
- Middle-stage caregiving. Alzheimer’s Association. https://www.alz.org/help-support/caregiving/stages-behaviors/middle-stage. Accessed Aug. 23, 2024.
- Kellerman RD, et al. Alzheimer’s disease. In: Conn’s Current Therapy 2024. Elsevier; 2024. https://www.clinicalkey.com. Accessed Aug. 23, 2024.
- Ferri FF. Alzheimer disease. In: Ferri’s Clinical Advisor 2025. Elsevier; 2025. https://www.clinicalkey.com. Accessed Aug. 23, 2024.
- Early-stage caregiving. Alzheimer’s Association. https://www.alz.org/help-support/caregiving/stages-behaviors/early-stage. Accessed Aug. 23, 2024.
- Alzheimer’s disease at a glance. National Center for Complementary and Integrative Health. https://nccih.nih.gov/health/alzheimer/ataglance. Accessed Aug. 23, 2024.
- Budson AE, et al. Memory Loss, Alzheimer’s Disease, and Dementia. 3rd ed. Elsevier; 2022. https://www.clinicalkey.com. Accessed Aug. 23, 2024.
- Care in the late stages of Alzheimer’s disease. National Institute on Aging. https://www.nia.nih.gov/health/coping-late-stage-alzheimers-disease. Accessed Aug. 23, 2024.
- Graff-Radford J, et al. New insights into atypical Alzheimer’s disease in the era of biomarkers. The Lancet. Neurology. 2021; doi:10.1016/S1474-4422(20)30440-3.
- Naureen Z, et al. Dietary supplements in neurological diseases and brain aging. Journal of Preventve Medicine and Hygience. 2022; doi:10.15167/2421-4248/jpmh2022.63.2S3.2759.
- Is Alzheimer’s genetic? Alzheimer’s Association. https://www.alz.org/alzheimers-dementia/what-is-alzheimers/causes-and-risk-factors/genetics. Accessed Aug. 23, 2024.
- Nimmagadda R. Allscripts EPSi. Mayo Clinic. July 17, 2024.
- Alzheimer’s disease research centers. National Institute on Aging. https://www.nia.nih.gov/health/alzheimers-disease-research-centers#minnesota. Accessed Aug. 23, 2024.
- About the Alzheimer’s Consortium. Arizona Alzheimer’s Consortium. https://azalz.org/about/#institutes. Accessed Aug. 23, 2024.
- Lewis JE, et al. The effects of twenty-one nutrients and phytonutrients on cognitive function: A narrative review. Journal of Clinical and Translational Research. 2021; doi:10.15167/2421-4248/jpmh2022.63.2S3.2759.
- Home safety. Alzheimer’s Association. https://www.alz.org/help-support/caregiving/safety/home-safety. Accessed Aug. 27, 2024.
- Argyriou S, et al. Beyond memory impairment: The complex phenotypic landscape of Alzheimer’s disease. Trends in Molecular Medicine. 2024; doi:10.1016/j.molmed.2024.04.016.
- Grant WB, et al. Diet’s role in modifying risk of Alzheimer’s disease: History and present understanding. Journal of Alzheimer’s Disease. 2023; doi:10.3233/JAD-230418.
- Wolk DA, et al. Clinical features and diagnosis of Alzheimer disease. https://www.uptodate.com/contents/search. Accessed Aug. 30, 2024.
- Jack Jr. CR, et al. Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s Association Workgroup. Alzheimer’s & Dementia. 2024; doi:10.1002/alz.13859.
- 2024 Alzheimer’s disease facts and figures. Alzheimer’s Association. https://www.alz.org/alzheimers-dementia/facts-figures. Accessed Aug. 26, 2024.
- Rosenberg A, et al. Multidomain interventions to prevent cognitive impairment, Alzheimer’s disease and dementia: From FINGER to World-Wide FINGERS. Journal of Prevention of Alzheimer’s Disease. 2020; doi:10.14283/jpad.2019.41.
- Huang L, et al. Mediterranean-dietary approaches to stop hypertension intervention for neurodegenerative delay (MIND) diet and cognitive function and its decline: A prospective study and meta-analysis of cohort studies. The American Journal of Clinical Nutrition. 2023; doi:10.1016/j.ajcnut.2023.04.025.
- Fortea J, et al. APOE4 homozygozity represents a distinct genetic form of Alzheimer’s disease. Nature Medicine. 2024; doi:10.1038/s41591-024-02931-w.
- Ashton NJ, et al. Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology. JAMA Neurology. 2024; doi:10.1001/jamaneurol.2023.5319.
- Palmqvist S, et al. Blood biomarkers to detect Alzheimer disease in primary care and secondary care. JAMA. 2024; doi:10.1001/jama.2024.13855.
- Leqembi (approval letter). Biologic License Application 761269. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761269. Accessed Sept. 5, 2024.
- Liu E, et al. Updates in Alzheimer’s disease: From basic research to diagnosis and therapies. Translational Neurodegeneration. 2024; doi:10.1186/s40035-024-00432-x.
- Shi M, et al. Impact of anti-amyloid-β monoclonal antibodies on the pathology and clinical profile of Alzheimer’s disease: A focus on aducanumab and lecanemab. Frontiers in Aging and Neuroscience. 2022; doi:10.3389/fnagi.2022.870517.
- Lecanemab injection. Facts & Comparisons eAnswers. https://fco.factsandcomparisons.com. Accessed Sept. 6, 2024.
- Kisunla (approval letter). Biologic License Application 761248. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761248. Accessed Sept. 6, 2024.
- Donanemab injection. Facts & Comparisons eAnswers. https://fco.factsandcomparisons.com. Accessed Sept. 6, 2024.
- Kang C. Donanemab: First approval. Drugs. 2024; doi:10.1007/s40265-024-02087-4.
- Serafin P, et al. Air pollution: A silent key driver of dementia. Biomedicines. 2023; doi:10.3390/biomedicines11051477.
